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Abstract (word count: 350/350) 
Background: &XVKLQJ¶VGLVHDVH LVDUDUHdeleterious condition in which few prospective, 
interventional studies have been conducted. This manuscript reports results of the first 
Phase III study evaluating long-acting intramuscular pasireotide in patients with CXVKLQJ¶V
disease.  
 
Methods: Patients with persistent/recurrent or de novo (non-surgical candidates) &XVKLQJ¶V
disease and mean urinary free cortisol (mUFC; of three 24-hour samplesā5±5·0x upper 
limit of normal (ULN; N=150) were randomised (double blind) using an interactive-response-
technology system to pasireotide 10mg or 30mg every 4 weeks. Randomisation was 
stratified by screening mUFC (1·5±<2·0xULN and 2·0±5·0xULN). The dose could be up-
titrated (10 to 30mg/30 to 40mg) at month 4 if mUFC>1·5xULN and/or months 7, 9, 12 if 
mUFC>1·0xULN. Primary endpoint: patients achieving mUFCULN at month 7 regardless 
of dose titration. Efficacy analyses were based on intention to treat. This trial is registered 
with ClinicalTrials.gov: NCT01374906. 
 
Findings: Between 28 December 2011 and 9 December 2014, 150 patients were 
randomised to receive pasireotide 10mg (n=74) or 30mg (n=76). The primary efficacy 
endpoint (mUFC8/1at month 7) was met by 31/74 (41·9%; 95%CI:30·5,53·9) patients in 
the 10mg group and 31/76 (40·8%; 95%CI:29·7,52·7) patients in the 30mg group. The most 
common adverse events (10mg and 30mg groups, respectively) were hyperglycaemia 
(36/74 [48·6%] and 36/76 [47·4%]), diarrhoea (26/74 [35·1%] and 33/76 [43·4%]), 
cholelithiasis (15/74 [20·3%] and 34/76 [44·7%]), diabetes mellitus (14/74 [18·9%] and 
18/76 [23·7%]), and nausea (15/74 [20·3%] and 16/76 [21·1%]). Serious adverse events 
suspected to be study drug related were reported in 8/74 (10·8%) and 4/76 (5·3%) of 
patients in the 10mg and 30mg groups. Two patients died during the study (pulmonary 
artery thrombosis; cardiorespiratory failure); neither was judged to be related to study drug. 
 
Interpretation: Long-acting pasireotide normalised mUFC in ~40% of patients with 
&XVKLQJ¶V GLVHDVH at month 7 and had a similar safety profile to that of twice-daily 
subcutaneous pasireotide. Long-acting pasireotide is an effective treatment option for some 
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SDWLHQWV ZLWK &XVKLQJ¶V GLVHDVH who have failed or are not candidates for surgery and 
provides a convenient monthly administration schedule. 
 
Funding: Novartis Pharma AG. Financial support for medical editorial assistance was 
provided by Novartis Pharmaceuticals Corporation. 
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Introduction 
&XVKLQJ¶V GLVHDVH Ls a rare condition characterised by adrenal overproduction of cortisol 
secondary to an adrenocorticotropic hormone (ACTH)-secreting pituitary tumour 
(corticotropinoma).1 Prolonged exposure to supraphysiological cortisol levels is associated 
with multisystem morbidity, which contributes to impaired quality of life and excess 
mortality.2,3 Prompt treatment and long-term control of cortisol excess is crucial in 
preventing clinical complications and reducing mortality DVVRFLDWHG ZLWK &XVKLQJ¶V
disease.1±5 
 
Surgical resection of the causative pituitary adenoma is the first-line treatment of choice for 
PRVWSDWLHQWVZLWK&XVKLQJ¶VGLVHDVH, which leads to remission in over 75% of patients if 
performed by an expert pituitary surgeon.6 However, surgery is not always successful and 
disease recurrence can occur several years after initial remission, while some patients 
refuse or are not candidates for surgery.6 As a result, many patients require additional 
treatment RSWLRQVIRUWKHPDQDJHPHQWRI&XVKLQJ¶VGLVHDVH. Owing to its rarity (estimated 
incidence and prevalence: 1·2±2·4 and 39 per million population, respectively),7,8 few 
SURVSHFWLYH VWXGLHVRIPHGLFDO WKHUDSLHVKDYHEHHQ FRQGXFWHG LQ SDWLHQWV ZLWK&XVKLQJ¶V
disease. All currently approved medical therapies for &XVKLQJ¶V GLVHDVH UHTXLUH GDLO\
administration, either orally or by injection,2 which can represent a burden for patients with 
chronic diseases.9  
 
Pasireotide is a multireceptor-targeted, second-generation somatostatin analogue with 
highest affinity for somatostatin receptor subtype 5 (SSTR5), the most abundantly 
expressed SSTR in corticotropinomas.10 Twice-daily, subcutaneous pasireotide (Signifor®) 
is approved in many countries worldwide, including the USA and EU, for treatment of adults 
ZLWK&XVKLQJ¶VGLVHDVH.6 An intramuscular long-acting formulation suitable for once-monthly 
administration has been developed.11 While long-acting pasireotide has been approved for 
the treatment of acromegaly,12,13 it had not yet EHHQ WHVWHG LQ SDWLHQWV ZLWK &XVKLQJ¶V
disease. This manuscript describes results of the first Phase III study of long-acting 
pasireotide LQSDWLHQWVZLWK&XVKLQJ¶VGLVHDVH. 
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Methods 
Study design 
This was a prospective, multicentre, randomised-dose (double-blind), Phase III study 
(Clinical Trial Registration Number: NCT01374906) comprising a 12-month core phase and 
an optional, open-ended extension. The study was conducted at 57 sites (19 countries) in 
accordance with the Declaration of Helsinki; an independent ethics committee/institutional 
review board for each site approved the study protocol. Patients provided written informed 
consent to participate. 
 
Patients 
Key inclusion criteria: age \HDUV and confirmed diagnosis of persistent, recurrent, or de 
novo (if not surgical candidates) &XVKLQJ¶VGLVHDVH with: mean 24-hour urinary free cortisol 
(mUFC) 1·5±5·0x upper limit of normal (ULN), calculated from three 24-hour samples 
collected within 2 weeks before study entry; normal/above-normal morning plasma ACTH; 
confirmed pituitary source of &XVKLQJ¶VV\QGURPH (Supplementary Methods). 
 
Key exclusion criteria: any previous pasireotide treatment; mitotane therapy within 6 
months; pituitary irradiation within 10 years (Supplementary Methods).  
 
Randomisation and blinding 
After a 30-day screening period and washout of &XVKLQJ¶V GLVHDVH medications, patients 
were randomised 1:1 (using an interactive-response-technology system) in a double-blind 
manner to intramuscular pasireotide 10mg or 30mg every 28 days (Novartis Pharma AG, 
Basel, Switzerland) administered by site personnel (Supplementary Methods); see 
Supplementary Methods for dose-selection rationale. Randomisation to one of the two 
pasireotide dose regimens was stratified by screening mUFC (stratum 1: mUFC 1·5±
<2·0xULN; stratum 2: mUFC 2·0±5·0xULN). The dose was up-titrated (10 to 30mg/30 to 
40mg) at month 4 if mUFC>1·5xULN and/or at months 7, 9, or 12 (maximum: 40mg) if 
mUFC>1·0xULN, provided there were no tolerability issues. One dose-level reduction was 
permitted during the first 7 months for tolerability. Patients were returned to their 
randomised dose once the tolerability issue resolved, or discontinued treatment if the issue 
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persisted. Further dose reductions were permitted after month 7; if a dose of 5mg was not 
tolerated, the patient discontinued treatment.  
 
The sponsor study team was blinded to treatment allocation and dose until the month 7 
database lock. Investigators, patients, and site personnel were blinded to treatment 
allocation and dose until the month 12 database lock (ie, after all patients had reached 
month 12 or were withdrawn from the study).  
 
Study endpoints and assessments 
The primary objective was to assess the proportion of patients in each randomised dose 
group achieving the primary endpoint: P8)&ULN (ULN: 166·5nmol/24h [60·3µg/24h]) at 
month 7, regardless of dose titration at month 4 (classified as responders). 
 
Key secondary objective: to assess the proportion of patients in each group with 
mUFCULN at month 7 and without dose up-titration at month 4. Other pre-specified 
secondary objectives reported here were to evaluate for each group during the core study: 
proportion of SDWLHQWVZLWKP8)&8/1DWHDFKPRQWKSURSRUWLRQRISDWLHQWVDFKLHYLQJWKH
primary efficacy endpoint according to mUFC stratum; changes from baseline in mUFC at 
each month; effect on morning plasma ACTH, morning serum cortisol, continuous and 
categorical measures of clinical signs of hypercortisolism, and health-related quality of life 
(HRQoL) over time; safety profile and tolerability. The following secondary objectives will be 
published separately: frequency of controlled mUFC response from baseline to months 7 
and 12; predictability of early uncontrolled response to non-response at months 7 and 12; 
time to first controlled or partially controlled mUFC response; duration of controlled or 
partially controlled mUFC response; proportion of patients with controlled or partially 
controlled mUFC P8)&!8/1 EXW  UHGXFWLRQ IURP EDVHOLQH DW HDFK PRQWK 
pharmacokinetic exposures of long-acting pasireotide in patients with Cushing¶s disease. 
 
Pre-specified exploratory analyses reported here include: proportion of patients achieving 
the primary efficacy endpoint by sex; changes from baseline in late-night salivary cortisol 
and tumour volume for each group during the core study. Post hoc analyses included: 
proportion of patients achieving the primary efficacy endpoint by history of pituitary surgery 
and maximum tumour diameter at baseline; change in tumour volume by maximum tumour 
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GLDPHWHU DW EDVHOLQH SURSRUWLRQ RI SDWLHQWV ZLWK D  RU  FKDQJH LQFUHDVH RU
decrease) from baseline in tumour volume according to maximum tumour diameter at 
baseline; change in mUFC from baseline to month 12 according to tumour volume change 
from baseline to month 12. 
 
UFC values were determined by high-performance liquid chromatography±tandem mass 
spectrometry (normal: 15·9±166·5nmol/24h [5·8±60·3µg/24h]) at central laboratories (see 
Supplementary Methods for assay details). mUFC was calculated as the average of three 
samples collected over 2 weeks. Systolic and diastolic blood pressure (BP), body weight, 
waist circumference, and body mass index (BMI) were assessed at every visit. HRQoL 
(CushingQoL: worst±best QoL, 0±100) was assessed at months 2, 4, 7, 10, 12. Tumour 
volume was assessed by magnetic resonance imaging (MRI) at baseline and months 7 and 
12 and evaluated by a blinded central reader (Supplementary Methods).  
 
Safety analyses were based on adverse events (AEs) reported up to data cut-off (10 
November 2015), including data beyond month 12 for some patients. AEs were defined 
using Medical Dictionary for Regulatory Activities v18·1 and graded per National Cancer 
Institute Common Terminology Criteria for AEs v3·0. Serious AEs (SAEs) were reported 
according to standard definitions.14  
 
Statistical analysis 
Sample-size calculation was based on the primary endpoint. The primary efficacy responder 
rate for each dosing regimen was hypothesisHGWREH$VDPSOHVL]HRISDWLHQWV
per dose group would provide 88% power for the lower bound of the respective two-sided 
95% confidence interval (95%CI; Clopper±Pearson exact method) to exceed 15%; if the 
lower bound of the 95%CI was >15%, that group met the pre-specified threshold for the 
proportion of patients achieving the primary endpoint.  
 
Efficacy analyses were conducted using the intent-to-treat principle (based on randomised 
dose). For primary/key secondary endpoints, if the mUFC level was missing at month 7, 
values were imputed using last available measurement between months 4 and 7; patients 
who discontinued before month 4 were considered non-responders. Dose groups were 
assessed independently, with no direct between-group comparisons (Supplementary 
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Methods). Changes from baseline in secondary objectives are summarised descriptively; 
two-sided 95%CIs were calculated for mean changes in secondary objectives over time. 
 
Safety analyses were conducted according to first dose administered for patients who 
received dose of study drug and had a valid post-baseline safety assessment. For the 
statistical analyses, SAS software, version 9.4 (SAS Institute) was used. 
 
Role of funding source 
Novartis Pharma AG funded the study. Novartis Pharmaceuticals Corporation provided 
financial support for medical editorial assistance. Study sponsor: designed the trial in 
collaboration with several investigators; provided funding and organisational support; 
collected data; performed analyses; aided data interpretation and manuscript preparation. 
Study steering committee (AL, SP, BMKB, JNP) had unrestricted access to raw data. All 
authors had access to analysed data, reviewed the manuscript, and had final responsibility 
for the decision to submit for publication. 
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Results 
Patient population 
Between 28 December 2011 and 9 December 2014, 150 patients were randomised to 
pasireotide 10mg (n=74) or 30mg (n=76) every 28 days (Figure 1). 
 
Altogether, 104/150 (69·3%) patients completed 12 months of treatment (Table 1). At 
baseline, patient demographics and disease history were balanced between dose groups 
(Table 1). Approximately two-thirds of patients in each group had mUFC 2·0±5·0xULN at 
screening. One-hundred and seventeen patients (78%) had a measurable pituitary tumour 
on MRI; of these, 49 had a pituitary macroadenoma (PD[LPXPGLDPHWHUPP) [Table 1]. 
 
Efficacy 
Urinary free cortisol 
Most patients in each group had a decrease in mUFC from baseline to month 7 (Figure 2). 
 
The primary efficacy endpoint P8)&8/1DWPRQWK was met by 41·9% (95%CI: 30·5, 
53·9; n=31/74) and 40·8% (95%CI: 29·7, 52·7; n=31/76) of patients in the 10mg and 30mg 
groups, respectively. Of those patients who met the primary efficacy endpoint, 2/31 (10mg) 
and 0/31 (30mg) were classified as responders based on imputation of their last available 
measurement between months 4 and 7. Higher response rates were seen in patients with 
lower screening mUFC (Figure 3). Partial control was achieved in 4/74 (5·4%; 10mg) and 
10/76 (13·2%; 30mg) patients at month 7 (Supplementary Results). Overall, similar 
response rates were observed between males and females and between patients with and 
without prior surgery; response rates were numerically higher in patients with a 
macroadenoma (49·0%; n=24/49) versus a microadenoma (35·3%; n=24/68) at baseline, 
although this was seen only in the pasireotide 10mg arm (Supplementary Results).  
 
The proportion of patients achieving mUFCULN at month 7 with no prior dose up-titration 
was 28·4% (95%CI: 18·5, 40·1; n=21/74) and 31·6% (95%CI: 21·4, 43·3; n=24/76) in the 
10mg and 30mg groups. Thirty-one (10mg) and 28 (30mg) patients received dose up-
titration at month 4; of these, 10/31 (32·3%) and 7/28 (25·0%) had mUFCULN at month 7.  
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At month 12, 35·1% (95%CI: 24·4, 47·1; n=26/74) and 25·0% (95%CI: 15·8, 36·3; n=19/76) 
of patients in the 10mg and 30mg groups had mUFCULN; partial control was achieved in 
8/74 (10·8%; 10mg) and 13/76 (17·1%; 30mg) patients. Of patients who were classified as 
responders at month 7, 20/31 (64·5%; 10mg) and 15/31 (48·4%; PJKDGP8)&ULN at 
month 12. Six of 31 (19·4%; 10mg) and 13/31 (41·9%; 30mg) responders at month 7 had 
mUFC>ULN at month 12 (Supplementary Results); two of these patients (both in the 30mg 
arm) received a lower dose of long-acting pasireotide at month 11 compared with month 6. 
 
Median mUFC decreased within 1 month of treatment in both groups and remained below 
baseline to month 12 for ongoing patients (Figure 4). Median percentage change from 
baseline in mUFC was ±47·9% (10mg) and ±48·5% (30mg) at month 7, and ±52·5% and  
±51·9% at month 12. 
 
Plasma ACTH and salivary and serum cortisol 
Sustained reductions were seen in both groups for median morning plasma ACTH and late-
night salivary cortisol (Supplementary Results). Median percentage changes from baseline 
to month 12 in the 10mg and 30mg groups were, respectively: plasma ACTH, ±22·5% and  
±17·4%; late-night salivary cortisol, ±30·7% and ±23·7%. At baseline, 13·2% (n=9/68) and 
4·3% (n=3/69) of patients in the 10mg and 30mg arms, respectively, had normal late-night 
salivary cortisol levels compared with 30·2% (n=16/53) and 15·0% (n=9/60) of patients at 
month 7, and 25·0% (n=11/44) and 20·8% (n=10/48) of patients at month 12. 
 
Changes in serum cortisol levels were generally consistent with those seen for morning 
plasma ACTH and late-night salivary cortisol (Supplementary Results). Median percentage 
changes from baseline to month 12 for serum cortisol were ±9·2% and 0·1% in the 10mg 
and 30mg groups, respectively; for the 30mg group, median percentage changes of ±8.0% 
to  
±16.1% were seen at all other time points between months 7 and 11.  
 
Clinical signs and symptoms 
Clinical improvements were present at month 7 and improved further to month 12 
(Supplementary Results). Mean changes (95%CI) from baseline to month 12 in the 10mg 
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and 30mg groups were, respectively: systolic BP, ௅4·6mmHg (±9·9, 0·7) and ௅5·0mmHg  
(±8·8, ±1·3); diastolic BP, ௅3·4mmHg (±7·3, 0·4) and ௅3·1mmHg (±5·7, ±0·5); waist 
circumference, ௅4·5cm (±7·2, ±1·8) and ௅6·2cm (±8·7, ±3·6); BMI, ௅1·3kg/m2 (±1·8, ±0·8) 
and ௅2·6kg/m2 (±3·3, ±1·9); weight, ௅3·4kg (±4·8, ±2·0; 4.6% decrease) and ௅6·5kg (±8·3,  
±4·7; 8.6% decrease); CushingQoL, 6·4 (1·3, 11·6) and 7·0 (3·0, 10·9). Improvements were 
also seen in facial rubor, fat pads, DQG RWKHU FOLQLFDO VLJQV RI &XVKLQJ¶V GLVHDVH from 
baseline to months 7 and 12 (Supplementary Results). 
 
Tumour volume 
From baseline to month 12, median tumour volume decreased by 17·8% (10mg; n=35) and  
16·3% (30mg; n=38) (Supplementary Results). For patients with a macroadenoma 
PD[LPXP GLDPHWHU PP DW EDVHOLQH PHGLDQ WXPRXU YROXPH GHFUHDVHG E\ ·6% 
(10mg; n=15) and 11·6% (30mg; n=13) at month 12. Of these patients, 40·0% (10mg; 
n=6/15) and 38·5% (30mg; n=5/13) experienced Dtumour volume reduction at month 
12; one patient per JURXS H[SHULHQFHG D % increase (Table 2). Median mUFC levels 
decreased from baseline to month 12 in patients regardless of tumour volume change 
(Supplementary Results). 
 
Safety 
By data cut-off, the median treatment duration was 449 (10mg; range: 28±1393; 
interquartile range: 197±756) and 381 days (30mg; range: 28±1294; interquartile range: 
280±532). Overall, 73/74 (98·6%; 10mg) and 76/76 (100%; 30mg) patients experienced  
AE. Most commonly reported AEs were hyperglycaemia, diarrhoea, cholelithiasis, diabetes 
mellitus, and nausea (Table 3); most were of mild-to-moderate severity (grade 1±2). The 
most frequent grade 3±4 AE was diabetes mellitus. 
 
Nine of 74 (12·2%; 10mg) and 10/76 (13·2%; 30mg) patients discontinued treatment 
because of an AE (Supplementary Results). Two patients in the 30mg group died during the 
study: pulmonary artery thrombosis, n=1 (30 days after first injection); cardiorespiratory 
failure, n=1 (16 days after 16th injection [during extension phase]); neither was suspected to 
be drug related. SAEs were reported in 21/74 (28·4%) and 17/76 (22·4%) patients in the 
10mg and 30mg groups; the most commonly reported SAE was cholelithiaisis (10mg, 2·7% 
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[n=2/74]; 30mg, 2·6% [n=2/76]). Eight of 74 (10·8%) and 4/76 (5·3%) patients in the 10mg 
and 30mg groups, respectively, experienced an SAE that was suspected to be related to 
study drug. 
 
Hyperglycaemia-related AEs occurred in 53/74 (71·6%; 10mg) and 62/76 (81·6%; 30mg) 
patients; 17/74 (23·0%) and 18/76 (23·7%) experienced grade 3±4 events. Four patients 
per group (10mg, 5·4%; 30mg, 5·3%) discontinued treatment because of hyperglycaemia-
related AEs. No instances of diabetic ketoacidosis or hyperosmolar hyperglycaemic non-
ketotic syndrome were reported. 
 
Mean fasting plasma glucose (FPG) and glycated haemoglobin (HbA1c) increased within 1±
2 months of treatment. Mean (SD; range) HbA1c increased from 5·7% (0·6%; 4·5±7·4%) 
and 5·7% (0·7%; 4·5±7·6%) in the 10mg and 30mg groups at baseline, respectively, to 
6·4% (0.9%; 5·0±8·7%) and 6·8% (1·3%; 5·2±12·3%) at month 4, and to 6·9% (1·4%; 5·1±
10·2%) and 7·0% (1·4%; 4·8±11·7%) at month 12. At month 12, 58·3% (28/48) and 60·4% 
(32/53) of patients in the 10mg and 30mg groups, respectively, had HbA1c<7·0%. 
 
At baseline, 27/74 (36·5%; 10mg) and 33/76 (43·4%; 30mg) patients were diabetic, 12/74 
(16·2%) and 12/76 (15·8%) were pre-diabetic, and 35/74 (47·3%) and 31/76 (40·8%) had 
normal glucose tolerance (see Supplementary Methods for definitions). Of patients with 
normal glucose tolerance at baseline in the 10mg and 30mg arms, 13/35 (37·1%) and 7/31 
(22·6%) had a worst-reported value in the pre-diabetic range, and 19/35 (54·3%) and 21/31 
(67·7%) had a worst-reported value in the diabetic range. Seven of 12 (58·3%) and 11/12 
(91·7%) patients in the 10mg and 30mg arms who were pre-diabetic at baseline had a 
worst-reported value in the diabetic range. Of patients with normal glucose tolerance at 
baseline, 8/35 (22·9%; 10mg) and 13/31 (41·9%; 30mg) had last available HbA1cā5%; 
9/12 (75·0%) and 7/12 (58·3%) patients who were pre-diabetic at baseline had last 
available HbA1c·5% (Supplementary Results). Of patients with normal glucose tolerance 
or pre-diabetes at baseline, 18/47 (38·3%; 10mg) and 22/43 (51·2%; 30mg) were receiving 
antidiabetic medication (ADM) at last assessment; 8/11 (72·7%) and 14/14 (100%) diabetic 
patients not receiving ADM at baseline were receiving ADM at last assessment. Nine of 16 
(56·3%) and 10/19 (52·SDWLHQWVRQ$'0DWEDVHOLQHZHUHUHFHLYLQJDGGLWLRQDODJHQW
at last assessment (see Supplementary Results for HbA1c changes by ADM status).  
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Gallbladder/biliary-related AEs occurred in 18/74 (24·3%; 10mg) and 34/76 (44·7%; 30mg) 
patients; four underwent cholecystectomy. Of patients with normal baseline ultrasound 
results, 8/64 (12·5%; 10mg) and 24/67 (35·8%; 30mg) had detectable sludge/gallstones at 
last assessment. Fifteen patients per group experienced liver-safety-related AEs (10mg, 
20·3%; 30mg, 19·7%); 6/74 (10mg, 8·1%) and 5/76 (30mg, 6·6%) experienced grade 3±4 
AEs, most commonly increased gamma-glutamyltransferase. Two patients per group 
(10mg, 2·7%; 30mg, 2·6%) discontinued treatment because of liver-safety-related AEs; 
alanine aminotransferase levels remained elevated at last observation (42 [82U/L] and 54 
[166U/L] days after last pasireotide dose). No instances of jaundice or other symptoms of 
hepatic dysfunction were reported. 
 
Two patients in the 10mg arm experienced a grade 1 AE of decreased insulin-like growth 
factor 1 (IGF-1) without any associated symptoms; one of these patients initiated growth 
hormone (GH) replacement 2·5 years after AE onset. Another patient had an AE of GH 
deficiency (IGF-1 and GH below the normal range); no associated symptoms were reported 
and treatment was not adjusted (Supplementary Results). IGF-1 levels decreased during 
pasireotide treatment. The initial decrease, seen at months 1 and 3 (prior to any dose up-
titration), was greater in the 30mg arm. By month 7 (3 months after first permitted dose up-
titration), mean IGF-1 SD score (SDS) was similar in both arms and remained stable to 
month 12. Mean (SD) IGF-1 SDS in the 10mg and 30mg groups, respectively, was: 0.3 
(1.4) and 0.3 (1.2) at baseline; ±0.6 (1.5) and ±1.5 (1.4) at month 3; ±1.2 (1.6) and ±1.6 
(1.4) at month 7; ±1.0 (1.5) and ±1.4 (1.6) at month 12 (Supplementary Results). Newly 
occurring QTcF prolongation of >480ms occurred in two patients in the 30mg arm; events 
were sporadic and resolved without treatment interruption. No patients with QTcF 
prolongation of >480ms experienced arrhythmias or clinical symptoms associated with 
episodes of QTcF prolongation. Two patients per group experienced injection-site-related 
AEs; one event required temporary treatment interruption and medication for pain. 
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Discussion 
This first prospective trial of monthly SDVLUHRWLGHLQ&XVKLQJ¶VGLVHDVHmet the pre-specified 
threshold for the proportion of patients achieving the primary and key secondary endpoints; 
pasireotide normalised mUFC levels in approximately 40% of patients at month 7. Excluding 
patients who received a dose increase at month 4, around 30% of patients attained normal 
mUFC at month 7. Normal mUFC was more likely to be achieved in patients with a lower 
screening mUFC level (1·5±<2·0xULN). Nevertheless, pasireotide normalised mUFC in 
more than one-third of patients with higher screening mUFC (2·0±5·0xULN). 
 
The similar between-group response rates at month 7 may be due to dose up-titration at 
PRQWK WKHSURSRUWLRQRISDWLHQWVZLWKP8)&8/1ZDVFRQVLVWHQWO\KLJKHU LQ WKHPJ
group at each month up to month 4, but tended to be similar thereafter. Dose up-titration 
may be beneficial for some patients who do not achieve normalised mUFC levels at lower 
doses. 
 
In the Phase III study of twice-daily pasireotide, normal mUFC was achieved by 22·2% of 
SDWLHQWVZLWK&XVKLQJ¶VGLVHDVHDWPRQWKregardless of prior dose titration). Mean/median 
baseline P8)&OHYHOVZHUHKLJKHULQWKDWVWXG\HQWU\FULWHULRQP8)&1·5xULN; baseline 
mean/median, 6·5xULN/3·9xULN WKDQ LQ WKH FXUUHQW VWXG\ HQWU\ FULWHULRQ P8)&1·5±
5xULN; baseline mean/median, 2·8xULN/2·4xULN).15 As patients with lower baseline 
mUFC were more likely to attain normal mUFC in both studies, the higher response rates 
observed for long-acting pasireotide may have resulted from exclusion of patients with 
mUFC >5xULN. 
 
In both dose groups, reductions in mUFC were seen rapidly (within 1 month), with median 
levels remaining below baseline and close to ULN for the study duration. Decreases in 
mUFC were accompanied by reductions in morning plasma ACTH and late-night salivary 
cortisol. 
 
Assessment of late-night salivary cortisol levels has high sensitivity (>90%) for the 
GLDJQRVLV RI&XVKLQJ¶ GLVHDVH16,17 Consistent with these findings, 91% of patients in this 
study had elevated late-night salivary cortisol levels at baseline. Few studies have 
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investigated the value of late-night salivary cortisol in monitoring response to medical 
WUHDWPHQW LQ SDWLHQWV ZLWK &XVKLQJ¶V GLVHDVH ZLWK YDU\LQJ RXWFRPHV.18±21 As such, the 
potential role of late-night salivary cortisol during monitoring of medical treatment remains to 
be determined. In this study, normal late-night salivary cortisol levels were seen in 22±23% 
of patients at months 7 and 12. Further study is required to determine the effect of medical 
WKHUDSLHVRQWKHUHVWRUDWLRQRIQRUPDOFLUFDGLDQFRUWLVROVHFUHWLRQLQSDWLHQWVZLWK&XVKLQJ¶V
disease. 
 
Improvements in weight, waist circumference, BMI, and HRQoL were seen over 12 months, 
indicating a sustained clinical benefit. Improvements in systolic and diastolic BP were seen 
in the 30mg arm, with similar trends in the 10mg arm. These changes may be clinically 
relevant; reductions in diastolic and systolic BP of 2௅5mmHg can lower stroke risk by 
11·5௅13%,22 while modest weight loss (5±10%) is associated with significant improvement 
in cardiovascular risk in studies of patients with type 2 diabetes mellitus.23 Pasireotide 
treatment is associated with tumour volume reduction in patients with acromegaly and 
&XVKLQJ¶V GLVHDVH.13,24 In this study, over one-third of patients with a macroadenoma 
experienced a  UHGXFWLRQ LQ WXPRXU YROXPH DW PRQWK 12, with two patients 
H[SHULHQFLQJD LQFUHDVH. Changes in pituitary microadenoma volume are difficult to 
assess accurately by MRI and may not be clinically relevant. For optimal outcomes in 
SDWLHQWV ZLWK &XVKLQJ¶V GLVHDVH D PXOWLGLVFLSOLQDU\ WHDP approach to treatment decision 
making, including an experienced neurosurgeon, is required; in patients who have had 
failed/are not candidates for surgery, the potential effect of pasireotide-associated tumour 
shrinkage on any subsequent surgery should be considered. 
 
The observed safety profile of long-acting pasireotide was consistent with that of twice-daily 
SDVLUHRWLGHLQSDWLHQWVZLWK&XVKLQJ¶VGLVHDVH.15 Approximately 70% of patients completed 
 PRQWKV¶ treatment; 13% of patients discontinued because of AEs. Long-acting 
pasireotide may have more favourable gastrointestinal tolerability than the twice-daily 
formulation; the incidence of diarrhoea, nausea, and abdominal pain after 12 months was 
39%, 21%, and 15%, respectively, for long-acting pasireotide, compared with 58%, 52%, 
and 24% for twice-daily pasireotide.15 Gallstones are commonly associated with 
somatostatin analogue treatment but are rarely symptomatic or require surgery.15,25 In this 
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study, 20% (n=15; 10mg) and 45% (n=34; 30mg) of patients had cholelithiasis; four patients 
underwent cholecystectomy. Gallbladder ultrasound is advised at regular intervals during 
pasireotide treatment. There was a low incidence of grade 3±4 liver-safety-related AEs 
during the study, the most common being increased gamma-glutamyltransferase levels. 
 
As previously described for twice-daily pasireotide, hyperglycaemia-related AEs were the 
most commonly reported AEs of special interest, occurring in 72% and 82% of patients in 
the 10mg and 30mg groups, respectively, and leading to discontinuation in four patients per 
group. FPG and HbA1c increased soon after starting pasireotide (within 1±2 months), and 
approximately 50% of patients required initiation/adjustment of ADM. Of patients with 
normal glucose tolerance/pre-diabetes at baseline, 41% had last-available HbA1c in the 
diabetic range (>6.5%). At month 12, ~60% of patients in each group met the goal of 
HbA1c<7% set by the American Diabetes Association and European Association for the 
Study of Diabetes.26,27 Blood glucose levels should be closely monitored in patients treated 
with pasireotide and action taken, including initiation of glucose-lowering therapy, if 
necessary. Reductions in mean IGF-1 levels were seen within 1 month of initiating long-
acting pasireotide; levels stabilised by month 7. Most (over 80%) patients continued to have 
IGF-1 levels within the normal range at month 12 and no clinical symptoms were reported. 
Long-term evaluation of the effects of pasireotide on the GH/IGF-1 axis in patients with 
&XVKLQJ¶VGLVHDVH is warranted. 
 
It was not possible to include a control arm in this trial. Owing to the significant morbidity 
associated with extended periods of hypercortisolism, a placebo-controlled trial was 
considered unethical. Furthermore, at the time of study start, there was no approved or 
gold-VWDQGDUG PHGLFDO WUHDWPHQW IRU &XVKLQJ¶V disease across all participating countries, 
which precluded an active comparator arm. 
 
In conclusion, this large Phase III study demonstrated that long-acting pasireotide 
administered for 12 months can reduce mUFC levels, is associated with improvements in 
clinical signs and HRQoL, and has a similar safety profile to that of twice-daily pasireotide. 
Pasireotide is an effective treatment for some SDWLHQWV ZLWK &XVKLQJ¶V GLVHDVH who have 
failed or are not candidates for surgery and is generally well tolerated, while the long-acting 
formulation studied here provides a convenient monthly administration schedule.  
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Research in context 
Evidence before this study 
We searched PubMed for articles published up to June 2017, using terms related to 
&XVKLQJ¶V GLVHDVH WR LGHQWLI\ UHOHYDQW UHVHDUFK RQ WKH management of this debilitating 
endocrine disorder. 0RVWGUXJVXVHGLQWKHWUHDWPHQWRI&XVKLQJ¶VGLVHDVHGRQRWWDUJHW the 
underlying tumour but either inhibit cortisol synthesis or block the glucocorticoid receptor. 
Furthermore, most of these agents are not approvHGIRUXVH LQ&XVKLQJ¶VGLVHDVH but are 
used off-label based on small studies or retrospective case series, with varying results. In 
2012, the results of a 12-month Phase III study were published, demonstrating the clinical 
benefits of a twice-GDLO\VXEFXWDQHRXVIRUPXODWLRQRISDVLUHRWLGHLQSDWLHQWVZLWK&XVKLQJ¶V
disease. Based on the results of that trial, twice-daily pasireotide was approved in the EU, 
the USA, and other countries worldwide for the treatment of adult patients with this rare 
disorder. An intramuscular long-acting formulation of pasireotide was developed to allow for 
a once-monthly administration schedule. Whereas long-acting pasireotide has been recently 
tested in two Phase III trials in patients with acromegaly, it had not been tested in patients 
ZLWK&XVKLQJ¶VGLVHDVHSULRUWRWKHFXUUHQWVWXG\ 
 
Added value of this study 
This study confirms the efficacy and safety of SDVLUHRWLGHLQSDWLHQWVZLWK&XVKLQJ¶VGLVHDVH, 
with the long-acting formulation providing a convenient monthly administration schedule.   
 
Implications of all the available evidence 
NormalisDWLRQRIFRUWLVRO OHYHOV UHSUHVHQWVDNH\ WUHDWPHQWJRDO LQSDWLHQWVZLWK&XVKLQJ¶V
disease, which can improve the mortality rate towards that of the general population. The 
findings from this study indicate that long-acting pasireotide can normalise cortisol secretion 
and provide sustained clinical benefit to a significant proportion of patients with this rare, 
difficult-to-treat, and deleterious condition. Furthermore, a once-monthly administration 
schedule may allow greater convenience and adherence to treatment than twice-daily 
subcutaneous self-administration. As such, long-acting pasireotide can represent an 
effective WUHDWPHQWRSWLRQIRUSDWLHQWVZLWK&XVKLQJ¶VGLVHDVH 
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Figures 
Figure 1. Patient flow 
 
 
*Multiple reasons for exclusion could be given for individual patients 
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Figure 2. Absolute change in individual mUFC levels from baseline to month 7 
 
For patients without a mUFC measurement at month 7, only baseline values are shown. Five patients in 
WKHPJJURXSDQGVL[SDWLHQWVLQWKHPJJURXSKDGP8)&8/1DWEDVHOLQHP8)&ZDVā[8/1
[range: 1·6±4·5xULN] at screening, thus meeting the eligibility criterion); of these, 4/5 and 3/6 met the 
primary efficacy endpoint. Dashed line represents the ULN for UFC (166·5nmol/24h) 
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Figure 3 3URSRUWLRQ RI SDWLHQWV ZLWK P8)&8/1 DW PRQWK  DFFRUGLQJ WR P8)&
stratum  
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Figure 4. Median mUFC (nmol/24h) from baseline up to month 12 
 
Bars represent interquartile range. Dashed line represents the ULN for UFC (166·5nmol/24h). The 
numbers of patients contributing to the median and achieving normal mUFC at each time point are 
displayed under the X axis (long-acting pasireotide 10mg [red]/30mg [blue]) 
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Table 1. Summary of baseline demographics and patient disposition 
 Long-acting pasireotide 
 
10mg 
N=74 
30mg 
N=76 
Overall 
N=150 
Mean age, years 38·3 38·6 38·5 
Female, n (%) 58 (78·4) 60 (78·9) 118 (78·7) 
Median time since diagnosis, 
months (range) 22·3 (0·9±394·7) 22·4 (0·7±231·9) 22·3 (0·7±394·7) 
Screening mUFC stratum, n (%)    
āand <2·0xULN 25 (33·8) 25 (32·9) 50 (33·3) 
āand ā[8/1 49 (66·2) 51 (67·1) 100 (66·7) 
Pituitary adenoma, n (%)*    
   Microadenoma 34 (45·9) 34 (44·7) 68 (45·3) 
   Macroadenoma 20 (27·0) 29 (38·2) 49 (32·7) 
   No visible adenoma 17 (23·0) 12 (15·8) 29 (19·3) 
Baseline mUFC, xULN    
Mean (SD) 2·8 (1·5) 2·9 (2·0) 2·8 (1·8) 
Median 2·5 2·2 2·4 
&XVKLQJ¶VGLVHDVHstatus, n (%)    
Persistent/recurrent 59 (79·7)  64 (84·2)  123 (82·0)  
De novo 15 (20·3)  12 (15·8) 27 (18·0) 
Previous treatment, n (%)    
Surgery 59 (79·7) 64 (84·2) 123 (82·0) 
Medical therapy 32 (43·2) 30 (39·5) 62 (41·3) 
Patients completed, n (%)Á    
Month 4 65 (87·8) 69 (90·8) 134 (89·3) 
Month 7 54 (73·0) 62 (81·6) 116 (77·3) 
Month 12 50 (67·6) 54 (71·1) 104 (69·3) 
Patients with dose adjustments, n (%)    
GRVHXS-titration (up to month 12) 48 (64·9) 51 (67·1) 99 (66·0) 
GRVHreduction 17 (23·0) 24 (31·6) 41 (27·3) 
 30 
 
*Patients with an evaluable tumour measurement at baseline (3 patients in the 10mg arm and 1 patient in 
the 30mg arm did not have an MRI assessment at baseline); pituitary adenoma size defined by maximum 
diameter (microadenoma: >0±<10mm; macroadenoma: >10mm); Twenty-seven patients did not undergo 
pituitary surgery prior to study entry for the following reasons: patient refused surgery, n=15; poor 
candidate for surgery, n=11; lack of access to surgical facility, n=1; one patient in the 30mg arm had a 
GRFXPHQWHGKLVWRU\RI UDGLRWKHUDS\ IRU&XVKLQJ¶VGLVHDVH 17·1 years before receiving the first dose of 
long-acting pasireotide; ÁIn the first 4 months, 16 patients discontinued treatment (unsatisfactory 
therapeutic effect, n=5; AEs, n=5; consent withdrawal, n=4; protocol deviation, n=1; death, n=1). By 
month 7, a further 18 patients had discontinued treatment (unsatisfactory therapeutic effect, n=10; AEs, 
n=5; consent withdrawal, n=2; protocol deviation, n=1). By month 12, a further 12 patients had 
discontinued treatment (consent withdrawal, n=5; unsatisfactory therapeutic effect, n=3; AEs, n=3; 
protocol deviation, n=1). SD, standard deviation 
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Table 2. Proportion of patients with a  UHGXFWLRQ  LQFUHDVH DQG 
change (stable) in tumour volume from baseline to month 12, by maximum tumour 
diameter at baseline* 
 Pasireotide 10mg/28 days Pasireotide 30mg/28 days 
Maximum 
baseline tumour 
diameter n 

reduction, 
n (%) 
<20% 
change, 
n (%) 

increase, 
n (%) n 
 
reduction, 
n (%) 
<20% 
change, 
n (%) 
 
increase, 
n (%) 
<6mm 8 3 (37·5) 4 (50·0) 1 (12·5) 8 1 (12·5) 4 (50·0) 3 (37·5) 
6௅<10mm 12 6 (50·0) 5 (41·7) 1 (8·3) 17 12 (70·6) 5 (29·4) 0 (0·0) 
PP 15 6 (40·0) 8 (53·3) 1 (6·7) 13 5 (38·5) 7 (53·8) 1 (7·7) 
Overall 35 15 (42·9) 17 (48·6) 3 (8·6) 38 18 (47·4) 16 (42·1) 4 (10·5) 
*Patients were categorised according to maximum pituitary tumour diameter at baseline (range: 
3௅54mm). Tumour volume changes were calculated for patients with evaluable measurements at both 
baseline and month 12 
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7DEOH  0RVW IUHTXHQW DGYHUVH HYHQWV UHSRUWHG LQ  RI SDWLHQWV RYHUDOO
regardless of study drug relationship 
 
Pasireotide  
10mg/28 days (N=74) 
Pasireotide  
30mg/28 days (N=76) 
Overall 
(N=150) 
 
All grades, 
n (%) 
Grade 3/4, 
n (%) 
All grades, 
n (%) 
Grade 3/4, 
n (%) 
All grades, 
n (%) 
Grade 3/4, 
n (%) 
Hyperglycaemia 36 (48·6) 6 (8·1) 36 (47·4) 3 (3·9) 72 (48·0) 9 (6·0) 
Diarrhoea 26 (35·1) 0 33 (43·4) 0 59 (39·3) 0 
Cholelithiasis 15 (20·3) 2 (2·7) 34 (44·7) 2 (2·6) 49 (32·7) 4 (2·7) 
Diabetes mellitus 14 (18·9) 10 (13·5) 18 (23·7) 14 (18·4) 32 (21·3) 24 (16·0) 
Nausea 15 (20·3) 1 (1·4) 16 (21·1) 0 31 (20·7) 1 (0·7) 
Headache 18 (24·3) 0 10 (13·2) 1 (1·3) 28 (18·7) 1 (0·7) 
Nasopharyngitis 16 (21·6) 0 12 (15·8) 0 28 (18·7) 0 
Fatigue 12 (16·2) 0 14 (18·4) 0 26 (17·3) 0 
Abdominal pain 10 (13·5) 2 (2·7) 12 (15·8) 0 22 (14·7) 2 (1·3) 
Hypertension 10 (13·5) 7 (9·5) 12 (15·8) 7 (9·2) 22 (14·7) 14 (9·3) 
Hypoglycaemia 9 (12·2) 2 (2·7) 12 (15·8) 2 (2·6) 21 (14·0) 4 (2·7) 
Peripheral oedema  9 (12·2) 0 12 (15·8) 0 21 (14·0) 0 
Influenza 12 (16·2) 0 6 (7·9) 0 18 (12·0) 0 
Dizziness 9 (12·2) 1 (1·4) 8 (10·5) 0 17 (11·3) 1 (0·7) 
Urinary tract infection 8 (10·8) 0 9 (11·8) 0 17 (11·3) 0 
Of the 21 patients who experienced an AE of hypoglycaemia, 17 were receiving antidiabetic medication 
(insulin, n=10; oral antidiabetic medication, n=7); none of these events required hospitalisation or medical 
intervention. Of the 49 patients who experienced cholelithiasis, four required surgery, 24 required medical 
treatment, and two had a temporary interruption to long-acting pasireotide treatment. Hypocortisolism-
related AEs were reported in six (8·1%) and seven (9·2%) patients in the 10mg and 30mg groups, 
respectively. Injection-site-related AEs were reported in two patients each in the 10mg (2·7%; pain, n=1; 
haemorrhage, n=1) and 30mg (2·6%; pain, n=1; hypersensitivity, n=1) groups 
 
 
